Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cyclacel Pharma (CYCC) Reports Q2 Loss of $0.10
August 11, 2015 4:45 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.10), versus ($0.22) reported last year. Revenue for the quarter came in at $356 thousand, versus $296 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
... More